Mehraboon Irani of Nirmal Bang Securities remains negative on Ranbaxy. He says one should not buy the stock. "I don't see any reasons why Ranbaxy should be going up in a hurry at least from the present levels," he adds.
first published: May 30, 2013 04:51 pm
A collection of the most-viewed Moneycontrol videos.
Small town, Big tech: Sridhar Vembu on Zoho’s rural push, AI Bubble, SaaS consolidation & many more
Live: DAVOS 2026 Day 5 Highlights: Elon Musk, AI Innovations & India’s Investment Pitch
Budget 2026 Decoded ? Key Terms You Must Know | Inflation, Taxes & Spending
Live: Sensex tumbles 2,000 pts this week, Nifty gives up 25,100 | Closing Bell
